Miltefosine Failure and Amphotericin B Success in the Treatment of a Case of Cutaneous Leishmania Braziliensis in a Recent Traveler in Belize and Guatemala.

IF 0.8 Q4 INFECTIOUS DISEASES
Case Reports in Infectious Diseases Pub Date : 2025-07-05 eCollection Date: 2025-01-01 DOI:10.1155/crdi/6644758
Michelle Y Ko, Emilie Fowler, Amanda Scott, Daniel Z Uslan
{"title":"Miltefosine Failure and Amphotericin B Success in the Treatment of a Case of Cutaneous <i>Leishmania Braziliensis</i> in a Recent Traveler in Belize and Guatemala.","authors":"Michelle Y Ko, Emilie Fowler, Amanda Scott, Daniel Z Uslan","doi":"10.1155/crdi/6644758","DOIUrl":null,"url":null,"abstract":"<p><p>We report the case of a 53-year-old male with recent travel to Guatemala and Belize who was diagnosed with cutaneous leishmaniasis (CL). He was treated empirically with miltefosine with no improvement and switched to amphotericin B upon species identification of <i>L. braziliensis</i>, resulting in the resolution of his lesions. This case demonstrates that clinicians should recognize the importance of systemic therapy for treating complex CL, as well as the importance of identification of species type for tailoring treatments. Furthermore, while miltefosine has proven efficacious for CL in many New World locales, it has demonstrated lower cure rates for CL in Guatemala, and thus identification of the region of origin of the CL infection is imperative for further guiding treatment, which may vary according to the differences in drug potency or region-specific resistance rates.</p>","PeriodicalId":9608,"journal":{"name":"Case Reports in Infectious Diseases","volume":"2025 ","pages":"6644758"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255491/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crdi/6644758","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

We report the case of a 53-year-old male with recent travel to Guatemala and Belize who was diagnosed with cutaneous leishmaniasis (CL). He was treated empirically with miltefosine with no improvement and switched to amphotericin B upon species identification of L. braziliensis, resulting in the resolution of his lesions. This case demonstrates that clinicians should recognize the importance of systemic therapy for treating complex CL, as well as the importance of identification of species type for tailoring treatments. Furthermore, while miltefosine has proven efficacious for CL in many New World locales, it has demonstrated lower cure rates for CL in Guatemala, and thus identification of the region of origin of the CL infection is imperative for further guiding treatment, which may vary according to the differences in drug potency or region-specific resistance rates.

Abstract Image

Abstract Image

Abstract Image

米替弗辛失败和两性霉素B成功治疗最近在伯利兹和危地马拉旅行的一例皮肤性巴西利什曼原虫。
我们报告一例53岁男性最近前往危地马拉和伯利兹谁被诊断为皮肤利什曼病(CL)。经验性用药米替弗辛治疗无改善,经鉴定为巴西乳杆菌后改用两性霉素B治疗,其病变得以消退。该病例表明,临床医生应该认识到治疗复杂CL的全身治疗的重要性,以及识别物种类型对定制治疗的重要性。此外,虽然米替福辛已被证明对许多新世界地区的CL有效,但它在危地马拉的CL治愈率较低,因此确定CL感染的起源地区对于进一步指导治疗是必要的,这可能因药物效力或区域特异性耐药率的差异而有所不同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
64
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信